Traveling the Road to a Hepatitis C Cure:
The Need to Stay on a Path of Least Resistance

Program Description

Over the last few years, a number of rapidly evolving new treatment options for chronic hepatitis C virus (HCV) infection have become available, including the emergence of new direct-acting antiviral (DAA) agents. Treatment with these DAAs—which include 3 NS3-4A protease inhibitors, 5 NS5A inhibitors, and 2 NS5B polymerase inhibitors in multiple combination regimens for the management of 6 HCV genotypes—has led to dramatic advances in terms of treatment efficacy, with sustained virologic response rates greater than 95% and minimal associated side effects. Although monitoring of clinical response and adverse events has been greatly simplified, clinicians must consider many factors to determine the most appropriate DAA regimen, including HCV genotype and associated subtypes, presence of advanced fibrosis, and different resistance mutations. This series of Case Clinics addresses these concerns, with a focus on tailoring the treatment regimen for optimal results in specific patient populations.

Learning Objectives

At the conclusion of this educational activity, participants should be able to:

  • Select the appropriate direct-acting antiviral (DAA) agent for hepatitis C virus (HCV) infection based on viral genotypes (and subtype) and associated complications
  • Identify the emergence of HCV resistance-associated variants (RAVs) following treatment with selected DAA regimens
  • Implement strategies, including the spectrum of molecular testing protocols, to identify and monitor disease progression and treatment efficacy and potentially avert HCV treatment resistance
  • Facilitate better linkage of care among specialists and other providers to strengthen screening, treatment, and monitoring practices, particularly for underserved and marginalized populations

Each activity offers:

0.50 AMA PRA Category 1 CreditTM


Bruce Bacon, MD
Professor of Internal Medicine
James F. King Endowed
  Chair in Gastroenterology
Saint Louis University School of Medicine
St. Louis, MO

Andrew J. Muir, MD
Chief, Division of Gastroenterology
Professor of Medicine
Department of Medicine
Duke University Medical Center
Durham, NC

Mark Sulkowski, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Medical Director, Viral Hepatitis Center
Division of Infectious Diseases
Johns Hopkins Hospital
Baltimore, MD

Provided by

Produced by

These activities are supported by an
educational grant from Merck & Co., Inc.